Table 3. Summary of Reported Infection/Reinfection Incidences (per person, person-years).

1 Lumley et al. included 1- and 2-dose vaccination groups. For this analysis, only the 2-dose vaccination group was counted. 2 Satwik et al. data was not entirely provided in the publication. Data obtained via personal communication. 3 Gazit et al. described three models of study, with a matching comparison. For this analysis, Model 2 was used for NPI/V,    and PI/UV analysis and Model 3 was used for the PI/V group. An NPI/UV group was not reported in this study and therefore omitted from the analysis. 4 Risk ratios and differences calculated from Events/Person-Year figures 5 Pooled RR and risk differences adjusted and determined by M-H methods. 6 Time-at-risk not published in Shrestha et. al. manuscript. Estimated by taking a number of people in the group, multiplied by the length of    study (in years)  7 Noted that there is no difference in incidence between NPI/UV and NPI/V groups. The authors of this study were contacted, and relayed at vaccine efficacy of 28%, after adjustment by a Cox proportion regression. Additionally, the author notes the implementation of vaccination during the peak phase of Delta and the shorter follow-up in the vaccinated cohort.

Study	NPI/UV	NPI/V	PI/UV	PI/V	NPI/V vs. PI/UV	PI/UV vs PI/V
	Cases (N)	Cases (N)	Cases (N)	Cases (N)	RR [95% CI]4	RR [95% CI]4
	%	%	%	%	AR [95%CI]4	AR [95%CI]4
	Person-Years	Person-Years	Person-Years	Person-Years
	Events/P-Y	Events/P-Y	Events/P-Y	Events/P-Y
Pfizer [17]	164 (17,720)	8 (17,637)	1 (567)	1 (526)	0.21 [0.03-1.69]	0.93 [0.06-14.57]
	0.93%	0.05%	0.18%	0.19%	-0.013 [-0.046-0.019]	-0.001 [-0.049-0.046]
	2,242	2,237	60	56
	0.073	0.004	0.017	0.018
Moderna [18]	90 (14,730)	6 (14,312)	1 (334)	0 (341)	0.15 [0.02-1.21]	3.05 [0.13-73.39]
	0.63%	0.04%	0.30%	0.0%	-0.014 [-0.47-0.019]	0.017 [-0.029-0.063]
	2,787	2,387	59	60
	0.032	0.002	0.017	0.0
J&J  [19]	509 (19,544)	173 (19,514)	4 (2030)	3(2122)	4.46 [1.67-11.93]	1.40 [0.31-6.19]
	2.60%	0.89%	0.20%	0.14%	0.043 [0.029-0.058]	0.004 [-0.012-0.019]
	3,089	3,114	321	336
	0.164	0.056	0.012	0.009
RCT Pooled	763 (51,634)	187 (52463)	6 (2931)	4 (2989)	0.59 [0.04-8.28]5	1.45 [0.43-4.85]
	1.48%	0.36%	0.20%	0.13%	0.007 [-0.037--.051]5	0.004 [-0.010-0.019]
	8,118	7,738	439	453
	0.094	0.024	0.014	0.009
Shrestha et.al  [21]	2139 (15,317)	15  (28,836)	0 (1265)	0 (1265)	1.36 [0.08-22.71]	Not estimable
	14.0%	0.05%	0.0%	0.0%	0.0026 [-0.003-0.0081]	0.000 [-0.008-0.008]
	3,5116	5,8466	2566	2476
	0.609	0.002	0.0	0.0
Lumley et al. [22]1	635 (10,513)	2 (940)	12 (1273)	1 (974	0.85 [0.19-3.73]	2.03 [0.27-15.42]
	6.0%	0.21%	0.94%	0.10%	-0.003 [-0.032-0.025]	0.011 [-0.013-0.036]
	6,231	107	543	92
	0.102	0.019	0.022	0.011
Satwik et. al. [24]2	128  (790)	323 (2120)	5  (147)	4 (596)	5.01 [2.21-11.32]	4.48 [1.27-15.82]
	16.2%	15.2%	3.4%	0.67%	0.55 [0.4354-0.6775]	0.108 [-0.0090-0.225]
	182	430	36	129
	0.6857	0.6967	0.138	0.031
Gazit et. al. [25]3	-	640 (46,035)	108 (46,035)	20 (14,029)	5.93 [4.84-7.25]	1.65 [1.02-2.65]
		1.39%	0.23%	0.14%	0.056 [0.051-0.062]	0.005 [0.001-0.008]
		9,459	9,459	2,882
		0.068	0.011	0.007
OBS Pooled	2902(26,620)	980(77,931)	125(48,720)	25 (16,819)	3.71 [1.75-7.86]5	1.94 [1.17-3.21]5
	10.9%	1.26%	0.26%	0.15%	0.092 [0.031-0.153]5	0.0038 [-0.0036-0.011]5
	9,925	15,842	10,296	3,352
	0.292	0.062	0.012	0.007
Total Pooled	3665(78,254)	1167 (129,394)	131(51,651)	29(19,808)	1.86 [0.77-4.51]5	1.82 [1.21-2.73]5
	4.68%	0.90%	0.25%	0.15%	0.049 [0.0084-0.0893]5	0.0039 [0.001-0.007]5
	18,042	23,580	10,735	3,804